Sophiris Bio (SPHS) PT Lowered to $2.75 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts SPHS Hot Sheet
Price: $0.00 --0%
Rating Summary:
4 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 22 | New: 16
Rating Summary:
4 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 22 | New: 16
Join SI Premium – FREE
H.C. Wainwright analyst Joseph Pantginis lowered the price target on Sophiris Bio (NASDAQ: SPHS) to $2.75 (from $3.50) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Fortinet (FTNT) PT Lowered to $140 at Stifel
- Microsoft (MSFT) PT Raised to $700 at UBS on Solid Q1 Beat
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
